Thursday, February 25, 2021 New Initial Jobless Claims numbers are out this Thursday morning, as nearly every Thursday, with numbers far lower than expected and week over week: 730K new jobless claims were made last week, way down from the 845K projected. It’s also a whopping 111K lower than the previous month’s downwardly revised 841K. These are still historically high numbers overall, but toward the lower end of the current cycle, and a welcome sight. Continuing Claims, reported for the prior week, came in at 4.42 million — a more than 100K drop from the upwardly revised 4.52 million the week previous. Unlike Initial Claims, which shows a rather volatile 12-week chart, Continuing Claims have generated a steady stream downward. Of course, much of this has to do with workers expiring on longer-term claims moving over to Pandemic Unemployment Assistance (PUA), which took in another million Americans two weeks ago. One caveat to these weekly numbers was foreseen ahead of time by analysts: weather conditions in much of the country, especially in hard-hit Texas, look to have affected these figures to the downside temporarily. Thus, while we see relatively strong jobless claims numbers this week, we might expect either an upward revision next week, higher-than-normal headline numbers, or both. Currently, 19 million Americans claim some sort of unemployment insurance. The first revision to Q4 Gross Domestic Product (GDP) was also released ahead of today’s opening bell, dipping 10 basis points to 4.1%. It was still a good effort to get the U.S. economy closer to breakeven after the disastrous Q2 — any quarter in a “normal year” would be pleased as punch to see 4%+ growth. Keep in mind this growth in the final quarter of last year was without the benefit of an additional stimulus package we saw that brought much of Q3 back from Q2. Durable Goods Orders for January stormed past expectations this morning: +3.4% more than tripled the 1.0% analysts were looking for. This manufacturing metric also saw a big upward revision for December, from 0.5% originally reported to +1.2% this morning. The core read doubled expectations to +1.4% and ex-Transportation was still +0.9%. Non-defense, ex-Aircraft durables — ac proxy for general business spending — came in at +0.5%, the only lower figure in this set of numbers. Best Buy (beat earnings estimates by 2 cents to $3.48 per share, on $16.94 billion in sales which was short of the $17.19 billion expected. U.S. sales growth came in up 89.3%, which sounds great until you compare with the Q2 figure, +242%. As a result, shares are selling off 8% in the pre-market, following strong gains of 33% year to date. The company has not missed on its bottom line since Q3 2017. BBY Quick Quote BBY - Free Report) Zacks Rank #1 (Strong Buy) Moderna (yesterday upped its Covid vaccine estimates of delivered doses to 700 million for 2021, nicely beyond the 600 million in the previous guide. This morning, the independent pharma firm missed bottom-line estimates by a wide margin: -69 cents per share versus -25 cents expected, and nearly double the year-ago -37 cents per share. But revenues in the quarter posted a tremendous beat: $570.7 million versus $326.6 million analysts were looking for. And more sales are what investors expect from a company like Moderna. MRNA Quick Quote MRNA - Free Report) Wayfair (also easily surpassed estimates on its bottom line: $1.24 per share was a big beat over 91 cents expected, and fully another orbit than the -$2.80 per share reported in the year-ago quarter. The online home furniture and accessories company, a Zacks Rank #2 (Buy)-rated stock ahead of earnings, missed on the top-line for the quarter: $3.67 billion versus $3.75 billion expected, though still up big year over year. Shares are up nearly 5% in today’s pre-market. W Quick Quote W - Free Report) Questions or comments about this article and/or its author? Click here>> Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>